A Robust, Streamlined Approach to Bosutinib Monohydrate
Organic Process Research & Development2012Vol. 17(3), pp. 500–504
Citations Over TimeTop 20% of 2012 papers
Gregory J. Withbroe, Chris Seadeek, Kevin P. Girard, Steven M. Guinness, Brian C. Vanderplas, Rajappa Vaidyanathan
Abstract
This article describes a systematic approach used to streamline the process for the isolation of bosutinib monohydrate, a promiscuous solvate former. A thorough understanding of the complex solid form landscape was garnered, and this knowledge was used to develop a process that routinely delivered the correct solid form and excellent purity at the end of the last bond-formation step, without the need for additional recrystallization and/or solid form conversion steps.
Related Papers
- → Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension(2016)43 cited
- → Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview(2013)16 cited
- → The safety of Bosutinib for the treatment of chronic myeloid leukemia(2017)13 cited
- → Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia(2013)9 cited